SCHEMBL13680419

SCHEMBL13680419

Cc1ccccc1Oc1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 6/20 0.50
SLC6A2 P23975 4/20 0.50
HTR1A P08908 3/20 0.50
SLC6A3 Q01959 3/20 0.50
AR P10275 3/20 0.47
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
FFAR1 O14842 2/20 0.45
FFAR4 Q5NUL3 1/20 0.45
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44
TSHR P16473 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HTR2A P28223 2/20 0.44
HPGD P15428 1/20 0.43
ACHE P22303 1/20 0.42
GCK P35557 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17624247 0.87 SLC6A4 (0.46) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1
SCHEMBL6290334 0.86 SLC6A4 (0.57) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1
SCHEMBL6289773 0.85 SLC6A4 (0.49) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1
SCHEMBL6293111 0.84 SLC6A4 (0.55) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1
SCHEMBL6290492 0.84 SLC6A4 (0.55) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1
SCHEMBL6290645 0.84 SLC6A4 (0.55) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1
SCHEMBL6290672 0.84 SLC6A4 (0.55) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1
SCHEMBL6289868 0.83 SLC6A4 (0.48) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1
SCHEMBL6936237 0.83 DHFR (0.48) SLC6A4SLC6A2HTR1ASLC6A3AR
SCHEMBL6289809 0.82 SLC6A4 (0.54) SLC6A4SLC6A2HTR1ASLC6A3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170253592-A1 N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM SHIRE INTERNATIONAL GMBH (CH) 2017-09-07 US disclosed
US-20170253615-A1 Spirocyclic derivatives SHIRE INTERNATIONAL GMBH (CH) 2017-09-07 US disclosed
WO-2016042453-A1 N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM SHIRE INTERNATIONAL GMBH (CH) 2016-03-24 WO disclosed
WO-2016042452-A1 Spirocyclic derivatives SHIRE INTERNATIONAL GMBH (CH) 2016-03-24 WO disclosed
US-7582664-B2 Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2009-09-01 US disclosed
US-7582664-B2 Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253592-A1 N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM SLC6A3, SLC6A2, SLC6A19 SLC6A4 12/4885SLC6A2 2/4885HTR1A 111/4885
US-20170253615-A1 Spirocyclic derivatives SLC6A3, SLC10A1, ABCB11 SLC6A4 17/4885SLC6A2 4/4885HTR1A 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.